Advertisement

Advertisement
Genomics/Genetics
Lung Cancer

FDA Approves Entrectinib for NTRK-Fusion Cancers, ROS1-Positive NSCLC

The U.S. Food and Drug Administration (FDA) granted accelerated approval to entrectinib (Rozlytrek) for adult and adolescent patients...

Genomics/Genetics
Issues in Oncology

How Technology Is Transforming the Assessment of Inherited Cancer Risk

ASCO published its first statement on genetic testing and its impact on oncology practice over 2 decades ago. Since then, ASCO has revised the statement...

Leukemia
Geriatric Oncology
Health-Care Policy
Immunotherapy

Ibrutinib and Rituximab vs Standard Chemoimmunotherapy in CLL

This week, we review a report on the combination of ibrutinib and rituximab vs standard chemoimmunotherapy in some patients...


Advertisement
Hematologic Malignancies

FDA Approves Fedratinib for Myelofibrosis

The U.S. Food and Drug Administration (FDA) approved fedratinib (Inrebic) for adults with intermediate-2 or high-risk primary or secondary...

Issues in Oncology

Eighth Edition of the AJCC Staging Manual Offers a More Personalized Approach to Patient Classification

This year marks the 60th anniversary of the creation of the American Joint Committee on Cancer (AJCC), whose founding mission was to standardize...

Advertisement




More Top Stories

Breast Cancer

Patricia A. Ganz, MD, on Breast Cancer: Whole- vs Partial-Breast Irradiation

Skin Cancer
Immunotherapy

Addition of IDO1 Inhibitor to Immunotherapy in Melanoma

As reported in The Lancet Oncology by Georgina V. Long, PhD, and colleagues, the phase III ECHO-301/KEYNOTE-252 trial showed no improvement in progression-free or overall survival with the addition of the IDO1 inhibitor epacadostat to pembrolizumab in unresectable stage III or stage IV melanoma. ...

Advertisement

Relapse of Nonseminomatous Germ Cell Tumors During Active Surveillance

In a single-institution study reported in the Journal of Clinical Oncology, Hamilton et al found that relapses of clinical stage I nonseminomatous germ cell tumors (NSGCT) during postorchiectomy active surveillance most frequently occurred in the retroperitoneum and were cured by single-modality...

Issues in Oncology
Health-Care Policy

Amy J. Davidoff, PhD, on Racial Disparities in Time to Cancer Treatment: The Effect of Medicaid Expansion

Issues in Oncology
Genomics/Genetics

How Technology Is Transforming the Assessment of Inherited Cancer Risk

ASCO published its first statement on genetic testing and its impact on oncology practice over 2 decades ago. Since then, ASCO has revised the statement three times, the most recent in 2015, in response to advances propelled by the sequencing and mapping of the human genome and the identification...

The Radium Era: 1916–1945

The text and photograph on this page are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photo below is from the volume titled “The Radium Era: 1916–1945.” The photograph appears ...

FDA Approves Entrectinib for NTRK-Fusion Cancers, ROS1-Positive NSCLC

Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to entrectinib (Rozlytrek) for adult and adolescent patients whose cancers have an NTRK (neurotrophic tyrosine receptor kinase) genetic fusion and for whom there are no effective treatments. Entrectinib was also...

Head and Neck Cancer
Immunotherapy

Danny Rischin, MD, on Head and Neck Squamous Cell Carcinoma: KEYNOTE-048 Trial on Pembrolizumab

WHO Releases Report on the Global Tobacco Epidemic

On July 26, 2019, the World Health Organization (WHO) issued a new report, “Global Tobacco Epidemic 2019,” to discuss national efforts being made to implement effective strategies from the WHO Framework Convention on Tobacco Control that have been proven to reduce the demand for tobacco....

Advertisement

FDA Review Finds No Increased Risk of Prostate Cancer With Parkinson's Disease Treatments Containing Entacapone

A U.S. Food and Drug Administration (FDA) review of additional data found no increased risk of prostate cancer with the use of entacapone to treat Parkinson’s disease. The FDA conducted this review after an earlier trial—the Stalevo Reduction in Dyskinesia Evaluation–Parkinson's...